Background: CSF-1 expression precedes renal injury in autoimmune MRL-lpr mice and is responsible for mac-
INTRODUCTION
Macrophages (MO) can initiate and promote renal injury. They are ubiquitous in interstitial and glomerular lesions both in experimental and human kidney diseases (1) . The mechanisms of MO accumulation in the kidney that foster tissue injury are therefore central to renal tissue destruction. In MRL/MpJ-lpr/lpr (MRL-lpr) mice, which MRL background in which nonfatal glomerular and interstitial lesions gradually develop, is required for the lpr mutation to accelerate the loss of renal function.
Colony stimulating factor-I (CSF-1) and granulocyte-macrophage colony-stimulating factor (GM-CSF) are hematopoietic cytokines which attract MO into tissues and are required for MO growth and differentiation (5, 6) . CSF-I may be central to the initiation and promotion of renal injury in MRL-lpr mice: it is detectable in the circulation and kidneys of MRL-lpr mice well in advance of renal injury, but not in other strains with the lpr gene, MRL/MpJ-+ + (MRL-+ +), or other normal strains (7) . CSF-1 increases in proportion to the severity of the kidney disease (7) , and it is produced primarily in glomeruli by mesangial cells which express a secreted and membrane form of the cytokine (8) , and to a lesser degree in the interstitium (2) . CSF-1 is required for the survival and proliferation of MO propagated from MRL-lpr glomeruli (2) . MO are concentrated in areas within the kidney that express CSF-I (2), and the loss of CSF-I expression cor- relates with the disappearance of M4 and the reversal of renal lesions (9) . These results indicate that CSF-1 initiates and promotes autoimmune renal injury in MRL-lpr mice. Strategies to introduce the CSF-I gene into the kidney are limited since tissue-specific promoters that would tailor molecules for expression in selected cells only within the kidney have not been found. Gene transfer into the kidney could locally deliver a selected cytokine, but with previous systems gene transfer has been shortlived and variable (I 0-1 3). We designed a novel approach capable of continually delivering CSF-1 into the kidney. Using a retroviral gene transfer system, we transfected CSF-1 and another MO growth factor, GM-CSF, into renal tubular epithelial cells (TEC), and then placed these genetically modified cells under the renal capsule of syngeneic strains. The result was stable expression of CSF-1 or GM-CSF in the kidney and circulation for sustained periods (weeks to months). We used this system to test the impact of sustained local and systemic delivery of MO growth factors or other cytokines on renal injury.
MATERIALS AND METHODS
Mice MRL-lpr, MRL-++, C3H/FeJ (C3H-++), and C3H-lpr mice were purchased from The Jackson Laboratory (Bar Harbor, ME, U.S.A.) and maintained in our virus-free facility on standard laboratory chow. Female mice were used in all experiments to control for variation between sexes.
Reagents
Tissue culture media and supplements were purchased from Gibco (14) . Briefly, kidneys were removed and renal cortices were minced, dispersed in collagenase solution, and then passed through a series of steel sieves (250, 150, 75, and 38 ,um). Cells that passed through the final sieve were collected, washed in HBSS, and resuspended in modified KI medium. The cells were incubated for 1 hr at 370C in culture dishes, and nonadherent cells were transferred to collagen (type IV)-coated plates. TEC were cultured until they were confluent (Day 7-10 in MRL-++ and C3H-++ TEC, and Day 10-14 in MRL-lpr). Finally, I X 106 TEC were plated on collagen-coated plates, and then infected with the recombinant retrovirus.
Retrovirus-Mediated Cytokine Gene Transfer into Cultured TEC CRIP packaging cell lines that produced helperfree recombinant retroviruses carrying cytokine genes were generated as previously described (15) (16) (17) which contains integrated proviral sequences necessary for encapsulation of the recombinant viral RNA. The resulting virus-producing cell line produces recombinant retroviruses which transfer the recombinant viral genome containing the selected cytokine gene into a suitable host cell. Producer cells were grown to subconfluence (5 x 106 cells on a 10-cm culture dish) in Dulbecco's modified Eagle's medium (DMEM) complete medium containing 10% calf serum, replenished with 10 ml of fresh medium and incubated for 18 hr. The virus-containing cell culture supernatant was harvested, filtered through a 0.45-,um membrane, and viral stocks were applied to TEC cultures (1 X 106 cells on a 10-cm culture dish) in the presence of 8 ,ug/ml polybrene for 18 hr. Following retroviral infection, TEC were replenished with KI medium, grown to confluence (5-6 day), and culture supernatants were collected to verify cytokine secretion. The bacterial ,3-galactosidase ((3-gal) gene (LacZ) was introduced into TEC coincidentally with CSF-1-encoding sequences ("cotransfection") to track genetically modified TEC.
Detection of CSF-1, GM-CSF, and ,8-gal in Genetically Modified TEC CSF-1, GM-CSF production by genetically modified TEC was determined in cultured cells by immunohistochemical analysis. We cultured TEC for 48 hr on tissue culture chamber slides, fixed these cells with 95% ethanol, and then stained for the presence of CSF-1, GM-C SF using the immunoperoxidase technique. We blocked endogenous peroxidase activity with 0.6% hydrogen peroxide (H202) and 0.2% sodium azide for 10 min, washed the TEC with 0.01 M Trisbuffered saline (TBS) containing 0.1% bovine serum albumin (BSA), and blocked endogenous avidin and biotin using an Avidin/Biotin blocking kit (Vector Laboratories, Burlingame, CA, U.S.A.). The TEC were then incubated with biotinylated rat anti-murine GM-CSF Ab (5 ,ug/ml) in a humidified chamber for 2 hr at room temperature, washed, and then exposed to avidinperoxidase complex using the Vectastain ABC Elite Kit (Vector Laboratories) to detect GM-CSF. For indirect detection of CSF-1, rabbit anti-CSF-1 sera incubation was followed with biotinylated goat anti-rabbit IgG for 1 hr at room temperature, and then exposed to avidin-peroxidase complex. TEC were then exposed to 3-3'-diamino-benzidine (0. 5 closed. The maximal number of TEC which the subcapsular space could accommodate was 5 x 106 TEC. The viability of TEC immediately before implantation (Lx) was >90% by trypan blue staining. We implanted TEC derived from C3H-+ + and MRL-lpr mice under the renal capsule of syngeneic strain with or without the lpr mutation. To exclude the possibility that the lpr mutation altered the TEC, we implanted C3H-lpr-derived TEC into C3H-++ recipients, and MRL-++ TEC into MRLlpr recipients. Recipient mice were bled before Ix and 7, 14, and 28 days post-Lx to evaluate cytokine levels in the circulation.
Histological Examinations
We removed the TEC-implanted (left) kidney, as well as the contralateral (right) kidney at 3, 7, 14, 28, 56, and 90 days post-Ix. The kidneys were halved and fixed in 10% phosphate-buffered formalin for paraffin-embedded sections or snapfrozen in OCT compound (Miles, Naperville, IL, U.S.A.). Paraffin-embedded tissue sections were stained by the hematoxylin and eosin method and evaluated by light microscopy. We assessed the accumulation of cells in the subcapsular site, and in the renal cortex by counting the maximum number of cell layers in the area with the most extensive pathology. Using paraffin-embedded sections we detected M4 and lymphocytes by the immunoperoxidase method using F4/80 and Ab to CD4, CD8, and B220 determinants (2) . Specificity controls included the replacement of primary Ab with normal rat IgG.
Tissue (3-gal activity was evaluated on frozen sections by incubation with X-gal solution using the same method for TEC cultures described above, with an additional incubation with the X-gal solution (1 hr) (12, 18) .
RESULTS
TEC Transfected with CSF-1 and GM-CSF Encoding Genes Constitutively Produce and Secrete High Levels of These Cytokines TEC will be identified by naming the introduced gene and the cell type (e.g., CSF-1 -TEC). CSF-1-TEC derived from C3H-+ + mice secreted high levels of CSF-1 into the supernatant when tested 1 week after retroviral infection (Table 1) . Similarly, GM-CSF-TEC secreted substantial amounts of GM-CSF into the supernatants after 1 week of culture. CSF-1 and GM-CSF were undetectable in 4 ± 0 and 0 ± 0 CFU, and increased to 25 ± 5 and 15 ± 10 CFU, respectively, 28 days post-Ix. Implants of unmodified TEC did not increase CSF-1 or GM-CSF in the circulation (Table 3) . (Table 7) . In contrast, GM-CSF-TEC induced renal injury in all age groups (4-20 weeks), and the extent of the lesion was always more severe than CSF-1-TEC.
CSF-1-TEC Remain in the Implant Site 13-gal-C SF-1-TEC ("co-infected" TEC) implanted under the renal capsule were detected by the presence of 13-gal. These cells were confined to the subcapsular space, and did not migrate into the renal cortex (Fig. 2 F and G) . ,B-gal could be detected in 30-40% of the cells in the subcapsular space 3 days post-Ix; the proportion decreased to <10% by 28 days post-Ix (Table 8A) "match" and the lpr mutation and strain background the "tinder", which when combined incite renal destruction.
The lpr mutation affects the gene encoding the Fas antigen (4). The abnormal Fas protein may be responsible for the animal's inability to delete autoreactive cells in the periphery by programmed cell death (apoptosis). The mutation may be partially responsible for the increase in T cells in the kidney of MRL-lpr mice (23, 24) . Since other mice with the lpr mutation such as C3H-lpr, do not have nephritis, the MRL background contributes to the mechanism of renal injury. Numerous cytokine changes are related to the lpr mutation (TNF, IL-6), the MRL background (IL-1, TNF) or both (25) (26) (27) (29) . Our studies would suggest that these therapeutic systemic doses would not promote kidney injury, even in patients with an autoimmune propensity. GM-CSF incites renal injury substantially more rapidly than CSF-1, perhaps because GM-CSF is a growth factor for granulocytes and Mo.
However, we did not detect more than an occasional granulocyte in any of the kidneys in which implantation of GM-CSF-TEC initiated renal injury. Thus, it is unlikely that granulocytes were responsible for increasing renal injury. However, it is possible that GM-CSF is more potent than CSF-1 as a chemoattractant and in inducing proliferation of Mo. In fact, we have determined that GM-CSF causes bone marrow M4P from MRL mice to proliferate 3-fold more than CSF- 1. Similarly, GM-CSF causes M4 in lungs to proliferate more than CSF-1 (30) . Another possible explanation for the more rapid induction of renal injury by GM-CSF may be related to the ability of GM-CSF to induce costimulatory molecules such as B7. Expression of B7 along with MHC Ia would promote T cell activation (31) . We are currently investigating these differing biologic functions so that we can identify the reason for the far more rapid impact of GM-CSF compared with CSF-1 in inciting renal destruction.
Renal damage in the tissue adjacent to the implant site remains evident several months after introduction of Mo growth factors. CSF-1 and GM-CSF are produced by TEC for more than several weeks; although levels in the circulation diminish, these genetically modified TEC might continue to secrete cytokine. Although GM-CSF incites a more rapid accumulation of cells than CSF-1, the extent of renal injury by 90 days post-Ix is similar. It is possible that spontaneous autoimmune reactions in MRL-lpr recipients influence the renal injury after several months. At that time, progression of pathology might no longer result from CSF-1-TEC or GM-CSF-TEC secreting cytokines. The cellular composition in these later lesions is predominantly lymphocytes, but there are many plasma cells and some Mo, similar to the perivascular infiltrates in untreated MRL-lpr mice. Since vascular endothelial cells in MRL-lpr kidneys express CSF-1 (2), it is possible that CSF-1 induces the lesions.
The finding that CSF-1 and GM-CSF incites more severe renal lesions in MRL-lpr than by C3H-lpr mice, and that MRL-lpr mice must be at least 6 weeks of age for CSF-1 to initiate an accumulation of M4 and T cells may relate to expression of CSF-1 and TNF-a in the kidney of MRL-lpr, but not C3H-lpr mice (2, 25) . M+, derived from MRL-lpr but not C3H-lpr, exposed to TNF-a along with CSF-1 proliferate more compared with CSF-1 alone (32). Since MRL-lpr mice may also express numerous unidentified molecules, we plan to determine which molecules are newly expressed in MRL-lpr between 4 and 6 weeks of age and absent in C3H-lpr kidneys.
In summary, we have established a novel gene transfer system to deliver cytokines specifically into the kidney. This approach is particularly valuable for identifying the impact of local as well as systemic overexpression of molecules on the kidney. Since CSF-1, TNF-a, and IL-6 are increased within the kidney and circulation in MRL-lpr mice, we have constructed a strategy to establish which of these cytokines are instrumental in initiating renal injury. We now report that CSF-1 expressed in the kidney of MRL-lpr mice initiates renal injury. In addition, we have recently established that IL-6 (manuscript submitted) and TNFa (manuscript in preparation) alone do not incite renal injury in mice with the lpr mutation. Thus, these studies offer a strategy to explore the impact of local and systemic cytokine production on renal injury.
